The effectiveness of combination of midazolam and remifentanil for moderate sedation in gastroscopy

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023868

Enrollment

Unknown

Registered

2019-06-15

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive disease

Interventions

Case series:midazolam or remifentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients undergoing gastroscopy; Aged 18 to 65 years; ASA I-III.

Exclusion criteria

Exclusion criteria: 1. Identification/ suspicion of abuse or long-term use of narcotic sedatives and analgesics; 2. BMI>28 kg/m2; 3. Mallampati grading = 3 grade; 4. General contraindications for the use of midazolam or remifentanil (i.e., allergic reactions etc.); 5. Respiratory rate <10/min; 6. Preexisting hypoxia (oxygen saturation < 90%).

Design outcomes

Secondary

Measure	Time frame
vital signs;satisfaction rating;	—

Primary

Measure	Time frame
The Observer's Assessment of Alertness/Sedation Scale;	—

Countries

China

Contacts

Public ContactYi Zou

Beijing Friendship Hospital, Capital Medical University

zouyi871123@126.com+86 10-63138780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026